Clinical trials: Cardiovascular Risk Management
- Condition Cardiovascular Risk Management
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Hypertension, Hypercholesterolemia
Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors
To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.
- Trial name
- CRUCIAL (NCT00407537)
- Testing
- Amlodipine besylate/atorvastatin calcium single pill combination
- Where
- 125 sites in Costa Rica, Croatia and 18 more
- Volunteers
- 1,531 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension and Cardiovascular Risk Factors
Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors
To assess the effect of single pill therapy on the management of hypertension and other cardiovascular risk factors (e.g., dyslipidemia) in Indian patients in whom the treating doctor has already considered that the…
- Trial name
- EXCEL (NCT00579254)
- Testing
- CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)
- Volunteers
- 112 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Multiple Myeloma
A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan
This is a survey among pharmacists who have instructed NINLARO therapy in ixazomib, lenalidomide and dexamethasone (IRD) dosing to patients with relapsed/refractory multiple myeloma (rrMM).
- Trial name
- NCT05882279
- Testing
- No Intervention
- Where
- Japan
- Volunteers
- 330 people
- Sponsor
- Takeda
Dyslipidemia, Hypertension
A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk
The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in greater percentage of patients achieving blood…
- Trial name
- TOGETHER (NCT00412113)
- Testing
- Amlodipine besylate, Amlodipine besylate/atorvastatin calcium single pill combination
- Where
- 51 sites in United States
- Volunteers
- 245 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents
Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support
The purpose of this study was to evaluate the implementation of inclisiran in a regional primary care setting in the UK Inclisiran, also known as KJX839, is a medication made to reduce the level of "bad" cholesterol…
- Conditions
- Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density Lipoprotein Cholesterol
- Trial name
- SPIRIT (NCT04807400)
- Testing
- Inclisiran, Behavioural Support, Background lipid lowering therapy
- Where
- 17 sites in United Kingdom
- Volunteers
- 892 people
- Sponsor
- Novartis Pharmaceuticals
Atrial Fibrillation, Heart Failure
Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure
The purpose of this study is to characterize the feasibility and impact of a diagnostic tool that may help clinicians identify when patients are at higher risk of visiting the hospital for a heart failure event.
- Trial name
- IDENTIFY-HF (NCT01486316)
- Testing
- Reveal XT® Insertable Cardiac Monitor, Heart Failure Risk Status Diagnostic
- Where
- 11 sites in United States
- Volunteers
- 24 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Hypercholesterolemia, Coronary Arteriosclerosis
Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)
This study is being conducted to compare the efficacy, safety, and tolerability of ezetimibe 10 mg coadministered with atorvastatin 10 mg versus atorvastatin 10 mg in Indonesian population with primary hypercholesterolemia.
- Trial name
- NCT00319449
- Testing
- Ezetimibe, Atorvastatin 10 mg
- Volunteers
- 22 people
- Sponsor
- Organon and Co
Obesity
A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients
The purpose of the study was to determine the long-term effect of sibutramine treatment on cardiovascular outcomes in overweight and obese patients at risk of a cardiovascular event.
- Trial name
- SCOUT (NCT00234832)
- Testing
- Sibutramine hydrochloride
- Where
- United States
- Volunteers
- 10,777 people
- Sponsor
- Abbott
HIV Infections, Dyslipidemias
Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)
This is a phase 2, randomized, double-blinded, placebo-controlled clinical trial. The intervention drug will be efprezimod alfa (intravenous [IV] infusion).
- Trial name
- CALIBER (NCT03960541)
- Testing
- Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein), Saline Solution
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)